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Abstract
High-throughput microarray technology has been widely applied in biological and medical decision-making research during
the past decade. However, the diversity of platforms has made it a challenge to re-use and/or integrate datasets generated
in different experiments or labs for constructing array-based diagnostic models. Using large toxicogenomics datasets
generated using both Affymetrix and Agilent microarray platforms, we carried out a benchmark evaluation of cross-platform
consistency in multiple-class prediction using three widely-used machine learning algorithms. After an initial assessment of
model performance on different platforms, we evaluated whether predictive signature features selected in one platform
could be directly used to train a model in the other platform and whether predictive models trained using data from one
platform could predict datasets profiled using the other platform with comparable performance. Our results established
that it is possible to successfully apply multiple-class prediction models across different commercial microarray platforms,
offering a number of important benefits such as accelerating the possible translation of biomarkers identified with
microarrays to clinically-validated assays. However, this investigation focuses on a technical platform comparison and is
actually only the beginning of exploring cross-platform consistency. Further studies are needed to confirm the feasibility of
microarray-based cross-platform prediction, especially using independent datasets.
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Introduction
Microarrays, as efficient tools to simultaneously monitor the
expression of tens of thousands of genes, have been widely applied
in both mechanistic and decision-making research during the past
decade [1–4]. The large number of commercially available
microarray platforms has expanded the use of the technology
and made it more widely available to different laboratories.
However, left unresolved is the issue of whether inter-platform
differences may conceal or confound biologically significant
information with respect to potential biomarkers and prediction
models. Thus, the concern that one needs to stay within a
particularly microarray platform manufacturer slows down the
identification and qualification of genomic biomarkers [5].
The extent to which different microarray technologies influence
the identification of differential gene expression has been
addressed by a large number of studies and is the subject of a
review paper [6]. Despite the conflicting information given by a
handful of early published studies where both concordance[7–9]
and discordance[10–12] between technologies was demonstrated,
the maturation of microarray technology and data analysis
methods has led to improved cross-platform correlations[6,13].
Moreover, the first phase of FDA-led Microarray Quality Control
project (MAQC-I) has further confirmed the reproducibility of the
identification of differentially expressed genes across different
platforms [5,14–16]. These studies suggest that similar results
should be expected regardless of microarray platform if appropri-
ate experimental and analysis protocols are applied, meaning that
mechanistic research can incorporate datasets from multiple
sources without significant concern about platform-specific affects.
The clinical use of array-based diagnostics is relatively late in
coming; this is partially due to the demand of a substantial number
of patient samples to be used for training, since estimates of a
predictor’s error rate during model construction are more prone to
be biased for small datasets[17]. Therefore, an attractive approach
would be the re-use of relevant pre-existing sets of expression
profiles as training data. Although researchers have demonstrated
that reciprocal validation can be achieved using different patient
cohorts and microarray platforms[18], few benchmark analyses
have been carried out until recently to confirm the feasibility of re-
using datasets obtained from different platforms for diagnostic
models. Based on the toxicogenomics datasets generated in phase
II of the MAQC project using both Rat Genome 230 2.0 Array
(Affymetrix platform) and Rat Oligo 2-color G4130A Array
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evaluated and confirmed that high cross-platform concordance of
predictive signature genes and classifiers can be achieved for
binary classification. However, in reality, decision-making is not
always binary. For example, subtype identification in disease
diagnosis[20,21], toxicant discrimination[22] and the stratification
of toxicity severity in drug risk/safety assessment[23] can, in most
cases, only be achieved using multiple-class prediction. Thus, the
consistency of microarray platforms with regard to multiple-class
prediction discussed in this study is also of importance to the future
success of microarray-based predictive models in clinical applica-
tion and safety evaluation.
The primary issue we addressed is the comparability of models
constructed from different platforms. We then further evaluated
cross-platform consistency with regard to whether predictive
signature features selected on one platform could be directly used
to train a model on the other platform and whether predictive
models trained using one platform could predict datasets from the
other platform with comparable performance. In this study, three
commonly-used multi-class machine learning algorithms were
applied: fuzzy k-nearest neighbors (FKNN)[24,25], linear discrim-
inant analysis (LDA)[26] and support vector machine (SVM)[27].
The results provide a baseline confirmation of the cross-platform
consistency of multiple-class prediction.
Materials and Methods
Datasets
The same datasets and the way in which they were divided
into training and test sets have been previously described [19]. All
data is MIAME compliant and the raw data are available through
GEO (series accession number: GSE16716) and ArrayTrack
(http://www.fda.gov/nctr/science/centers/toxicoinformatics/Array
Track/). Rather than a binary score, the outcome variable
selected was the RHI (Response to Hepatocellular Injury) score,
which ranges from 0 to 2 that are associated with the severity of
chemically-induced hepatotoxicity [23]. Briefly, the toxicoge-
nomics datasets for Affymetrix Rat Genome 230 2.0 Array with
31,099 probe sets (AFX) and Agilent Rat Oligo 2-color G4130A
Array with 22,075 probes (AGL) were profiled from the same set
of 418 samples (RNA isolated from the liver from each of the 318
treated and 100 control rats), resulting in 418 and 318 arrays,
respectively. For hybridizations performed on the Agilent
platform, each of the 318 treated samples was labeled and
hybridized against a pooled RNA sample generated from the
control samples.
A prerequisite for platform comparison is that all datasets are
represented by a common set of probes. Three different
approaches were used to identify probes associated with the same
transcript: SeqMap, RefSeq, and Unigene, resulting in 4860,
6312, and 9954 common transcripts[19], respectively. SeqMap is
a sequence-based approach to identifying common probes
generated, and was also used in the MAQC-I project [16].
RefSeq is a less restrictive method of matching Agilent probes with
Affymetrix probes based on the RefSeq database, while Unigene is
the least stringent approach for identifying matching probes across
platforms using the Unigene database.
Due to the technological difference in experimental design
between Affymetrix (intensity) and Agilent 2-color (ratio) plat-
forms, three analysis configurations (ACs 1-3, illustrated in Figure
S1) were designed to ensure that both datasets matched in
comparison. AC 1 utilized the original datasets (i.e., AFX intensity
vs. AGL ratio), while AFX datasets in AC 2 were converted to
ratio and compared with the AGL ratio data, and AGL datasets in
AC3 were converted to intensity and compared with the AFX
intensity data. Briefly, the Affymetrix ratio data was calculated
using its intensity data in a way similar to Agilent platform, i.e.,
treated samples were compared to an average of the correspond-
ing samples. In AC3, the intensity data in AGL is the average
value of Cy3 and Cy5 corresponding only to the treated samples.
Note that the 318 arrays profiled from the same samples using
both platforms were used in AC 2 and AC 3, while AFX in AC 1
retained the original 418 arrays. Combined with the three
classification algorithms (FKNN, LDA, SVM), a total of 27
comparisons were carried out, corresponding to 3 ACs, each with
3 classifiers, and each classifier having 3 probe-mapping methods.
Detailed information on the datasets, probe mapping procedures,
and ACs has been published previously [19,28,29].
Study design
Detailed information for the study design is illustrated in
Figure 1; additional information about model construction
procedures is available in Supplementary Methods. Both
AFX and AGL datasets were divided into the predefined training
and test sets. The analysis protocol starts with the construction of
the best classifier using either the AFX or AGL training set
(Figure 1(a)) and ends by using a best classifier to predict the test
sets of both platforms. Corresponding to different destinations,
three designs (Figure 1(b–d)) were utilized in this study.
To evaluate the performance of models constructed using
different platforms, a best classifier was developed independently for
both the AFX and AGL training data and then used to predict the
corresponding test set. This procedure was repeated 500 times,
resulting in 500 sets of predictions[1,30]. The performance of
models was then compared with respect to that of the overall
samples and those in each subclass.
Next, signature genes selected in the best classifier on the training
set of one platform (e.g., AFX) were transferred to the training set
of the other platform (e.g., AGL) to train another classifier. This
procedure was repeated 500 times, and the overall prediction
accuracy as well as the prediction accuracy for each subclass was
calculated and recorded.
Lastly, in order to evaluate whether classifiers developed from
one platform could perform well on the other platform, the whole
classifier (i.e., the best classifier) developed on the training set of one
platform (e.g., AFX) was transferred to predict the test set of the
other platform (e.g., AGL). The obtained prediction performance
of test sets from both platforms for the 500 repetitions of the
procedure were recorded and compared.
T-index
The T-index score proposed in our previous study[19] was also
used to evaluate the comparability of model performance metrics
(e.g., accuracy) obtained from the two platforms. The T-index is
defined as
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iterations (N=500), PA
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accuracies for the test sets of platforms A and B obtained from
500 iterations, respectively, and SD is the standard deviation of
(PA
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k). Note that T-index score ranges from 0 to 1, with a score
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PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16067Figure 1. Detailed information on the study design. (a) Approach to development of the best classifier. (b) Assessment of performance of the
best classifiers derived from different platforms. (c) Transferability of signature genes, i.e., whether predictive signature features selected in one
platform could be directly used to train a model in the other platform. (d) Transferability of classifiers, i.e., whether predictive models trained using
data from one platform could predict datasets profiled using the other platform with comparable performance.
doi:10.1371/journal.pone.0016067.g001
Figure 2. Comparison of different platforms. (a) Overall prediction accuracy for both test sets using models generated from each platform. Blue,
yellow and brown bars represent ‘SeqMap’, ‘RefSeq’, and ‘Unigene’ for AFX, while corresponding circles faced green are for AGL. (b) Prediction
accuracy for samples in each subclass using FKNN. (c) Prediction accuracy for samples in each subclass using LDA. (d) Prediction accuracy for samples
in each subclass using SVM.
doi:10.1371/journal.pone.0016067.g002
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words, a larger T-index score indicates better transferability.
Results and Discussion
This is a benchmark analysis to evaluate the feasibility of re-
using pre-existing datasets as training samples for multiple-class
prediction models. We focused on the following three questions:
First, do models constructed from different platforms have similar
predictive performance both overall and for individual sub-classes?
Second, can predictive signature genes selected from one platform
be used to directly train a model on another platform? Lastly, can
predictive classifiers trained on one platform perform well on data
generated using another platform?
Comparison of different microarray platforms
Figure 2(a) illustrates the overall prediction accuracy for models
trained from both platforms on corresponding test sets using different
combination of analysis configurations (ACs 1-3), probe matching
protocols (SeqMap, RefSeq, Unigene), and classification algorithms
(FKNN, LDA, SVM). No difference in predictive accuracy between
the AFX and AGL datasets was observed for AC 2 and AC 3;
however, AC 1 demonstrated slightly higher accuracy for AFX.
Generally, probe matching protocols and classification algorithms
showed no impact of overall predictive accuracy.
Figure 2(b–d) gives detailed illustrations of model perfor-
mance for samples using FKNN, LDA, and SVM as classification
algorithms, respectively. The nearly indistinguishable model
performance of the AFX and AGL datasets in AC 2 and AC 3
further confirmed the comparability of different microarray
platforms. Moreover, the consistently higher accuracy of AFX
for samples with score 0 in AC 1 (Figure 2(b–d)) implies that the
unexpected better performance of AFX in overall prediction
accuracy (Figure 2(a)) might be attributable to the additional 100
control samples in AFX over AGL. Further evidence for this was
given by the comparable performance of both platforms for overall
samples and those in each subclass shown in Figure S2, where the
100 control datasets were removed and only the 318 treated
samples were retained in the AFX dataset.
Generally, consistent model performance exists across different
microarray platforms for multiple-class prediction, both for the
complete set of samples and for those with different RHI scores,
regardless of the ACs, probe-mapping methods, and classification
algorithms. This strongly suggests that predictive models could be
successfully developed using different microarray platforms as long
as classifiers with the best performance could be constructed for
each platform.
Transferability of predictive signature genes
Figure 3(a–b) delineates the overall prediction accuracy for
both test sets when signature genes selected from one platform
were transferred to train a model in the other platform.
Corresponding results for samples in each subclass using different
classification algorithms are illustrated in Figure 3(c–d) and
Figure S3. Figure 3a shows very similar performance in AC 2
and AC 3 for a model trained and tested on AFX data and a
model using the same predictive features trained and tested on
AGL data. Likewise, Figure 3b shows similar performance in
ACs 2 and 3 for a model trained and tested on AGL data and a
model using the same predictive features trained and tested on
Figure 3. Transferability of predictive signature genes. (a) Overall prediction accuracy for both test sets using signature genes selected from
AFX (AFX to AGL). (b) Overall prediction accuracy for both test sets using signature genes selected from AGL (AGL to AFX). In (a) and (b), blue, yellow
and brown bars represent ‘SeqMap’, ‘RefSeq’, and ‘Unigene’ for AFX, while corresponding circles faced green are for AGL. (c) Prediction accuracy for
samples in each subclass using FKNN in the transfer of AFX to AGL. (d) Prediction accuracy for samples in each subclass using FKNN in the transfer of
AGL to AFX.
doi:10.1371/journal.pone.0016067.g003
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T-index scores higher than 0.8 for most cases shown in Tables S1
and S2. Note that the relatively lower T-index scores around 0.72
for samples with a score of 1 should be attributed to the apparently
worse performance in predicting such samples as shown in
Figure 3(c–d) rather than poor transferability. As to the
consistently higher performance of AFX in AC 1 for overall
samples and those with a score of 0, it might also be ascribed to the
additional 100 controls samples that were pooled for the AGL-
generated data. The overlap of model performance shown in
Figure S4 supports not only the interpretations mentioned above,
but also the successful transfer of signature genes using different
ACs and probe-mapping methods.
These results provide excellent evidence that predictive
signature genes selected from one platform can be successfully
transferred to train a predictive model in the other platform
regardless of the types of analysis configurations, probe-mapping
methods, and classification algorithms used, as long as the datasets
are capable of producing informative-enough predictive models
(i.e., intrinsic predictable). This has the potential to improve the
diagnostic use of array-based predictive models by avoiding the
additional work and complexity of selecting different predictive
signature genes for each platform, and allowing the combination
of smaller datasets from multiple platforms that are not large
enough on their own to obtain a highly informative gene set.
Transferability of predictive classifiers
Figure 4(a–b) depicts the overall prediction accuracy for both
test sets where predictive classifiers generated on one platform
were used to predict datasets profiled with the other platform.
Figure 4a shows that predictive models trained with AFX data
have similar predictive performance when applied to both AFX
and AGL data; Figure 4b shows the same for models trained with
AGL data, with the exception of AC 1. Combined with the
corresponding T-index scores around 0.78 (Table S3), the results
suggest that the transferability of predictive classifiers with respect
to the overall performance was acceptable, except for the transfer
of AFX to AGL using AC 1. Based on the previous observation of
the effect of the additional 100 control samples on the
transferability between AFX and AGL, we decided to conduct
another analysis using the 318 common samples. The resulting
decreased difference between the predictive accuracy for the AFX
and AGL test sets (Figure S5) further confirmed the acceptable
transferability of predictive classifiers. Moreover, further analysis
combining data sets from AFX and AGL platforms confirmed that
the classifiers trained by the combined data sets performed well for
independent data sets from both AFX and AGL platforms (Table
S4). Generally, probe-mapping methods and classification algo-
rithms did not evidently impact on either the overall model
performance or the transferability between different platforms.
The predictive performance for the individual sub-classes,
however, shows a much different pattern. As shown in
Figure 4(c–d) and Figure S6 in which different classification
algorithms were utilized, predictive models trained with AGL data
show similar performance when applied to the AGL or AFX test
set. Models built with the AFX data show greatly reduced
predictive accuracy in the AGL test set as compared to the AFX
test set, particularly for samples with scores of 1 or 2. This finding
was further verified by T-index scores around or smaller than 0.5
for many cases in Table S5. This performance deficit appears to
be consistent across both probe-mapping methods and classifica-
tion algorithms.
Figure 4. Transferability of predictive classifiers. (a) Overall prediction accuracy for both test sets using classifiers trained on AFX (AFX to AGL).
(b) Overall prediction accuracy for both test sets using classifiers trained on AGL (AGL to AFX). In (a) and (b), blue, yellow and brown bars represent
‘SeqMap’, ‘RefSeq’, and ‘Unigene’ for AFX, while corresponding circles faced green are for AGL. (c) Prediction accuracy for samples in each subclass
using FKNN in the transfer of AFX to AGL. (d) Prediction accuracy for samples in each subclass using FKNN in the transfer of AGL to AFX.
doi:10.1371/journal.pone.0016067.g004
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could predict datasets profiled using another platform with
acceptable overall predictive performance, despite slight differ-
ences between different directionality of transfer and analysis
configurations (ACs). However, when the transferability was
considered for each subclass, the performance of the test set that
corresponded to the data used to train the model was noticeably
better. Generally, the transferability of AFX to AGL was relatively
poor (especially for samples with RHI scores of 1 or 2), while the
transferability of AGL to AFX was much better. As was observed
consistently in this study, probe-mapping methods and classifica-
tion algorithms did not impact significantly on either model
performance or the overall transferability.
The diversity of microarray platforms has made it a challenge to
re-use and/or integrate datasets generated in different experiments
to construct array-based diagnostic models. Thus, in this study, we
investigated the consistency of multiple-class prediction models
generated using datasets from different platforms in three aspects:
the comparability of model performance from different platforms,
whether predictive signature genes selected from one platform
could be directly utilized to train another model on the other
platform, and whether classifiers trained from one platform could
predict datasets profiled from the other platform with comparable
performance. The results supported the potential applications in
biological and medical decision-making for cross-platform analyses
of both new and existing microarray datasets. Moreover, probe-
mapping methods and classification algorithms did not exert an
apparent affect on either model performance or consistency
between microarray platforms. However, the relatively high
concordance achieved in this benchmark investigation is only
the beginning of exploring cross-platform consistency because it is
based on two microarray datasets generated on identical biological
samples using different platforms, i.e., this investigation is mainly
focused on a technical platform comparison. Undoubtedly, further
studies are needed to confirm the feasibility of microarray-based
cross-platform prediction, especially using independent datasets.
Supporting Information
Figure S1 Three analysis configurations (ACs 1-3) used in this
study.
(TIF)
Figure S2 Model performance for AFX after removing the
additional 100 control samples in platform comparison using AC 1.
(TIF)
Figure S3 Transferability of predictive signature genes. (a)
Prediction accuracy for samples in each subclass using LDA in
the transfer of AFX to AGL. (b) Prediction accuracy for samples in
each subclass using LDA in the transfer of AGL to AFX. (c)
Prediction accuracy for samples in each subclass using SVM in the
transfer of AFX to AGL. (d) Prediction accuracy for samples in
each subclass using SVM in the transfer of AGL to AFX.
(TIF)
Figure S4 Model performance in transferability analysis of
predictive signature genes using AC 1 after removing the
additional 100 control samples in AFX.
(TIF)
Figure S5 Overall model performance for AC 1 in transferabil-
ity analysis of predictive classifiers after removing the additional
100 control samples in AFX.
(TIF)
Figure S6 Transferability of predictive classifiers. (a) Prediction
accuracy for samples in each subclass using LDA in the transfer of
AFX to AGL. (b) Prediction accuracy for samples in each subclass
using LDA in the transfer of AGL to AFX. (c) Prediction accuracy
for samples in each subclass using SVM in the transfer of AFX to
AGL. (d) Prediction accuracy for samples in each subclass using
SVM in the transfer of AGL to AFX.
(TIF)
Table S1 Overall prediction accuracy and corresponding T-
index scores for both platforms in transferability analysis of
predictive signature genes.
(DOC)
Table S2 T-index scores for samples in each subclass in
transferability analysis of predictive signature genes.
(DOC)
Table S3 Overall prediction accuracy and corresponding T-
index scores for both platforms in transferability analysis of
predictive classifiers.
(DOC)
Table S4 Prediction accuracy for models generated from the
combined data.
(DOC)
Table S5 T-index scores for samples in each subclass in
transferability analysis of predictive classifiers.
(DOC)
Methods S1
(DOC)
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